Ashford Capital Management Inc Supernus Pharmaceuticals, Inc. Transaction History

Ashford Capital Management Inc

$678 Million
Q1 2024

A detailed history of Ashford Capital Management Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Ashford Capital Management Inc holds 763,465 shares of SUPN stock, worth $20.7 Million. This represents 3.84% of its overall portfolio holdings.

Number of Shares

763,465

Previous 826,488 7.63%

Holding current value

$20.7 Million

Previous $23.9 Million 8.88%

% of portfolio

3.84%

Previous 3.48%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$27.11 - $35.17 $1.71 Million - $2.22 Million	-63,023 Reduced 7.63%	763,465 $26 Million
Q4 2023 Feb 14, 2024	SELL	$22.72 - $29.68 $2.05 Million - $2.68 Million	-90,259 Reduced 9.85%	826,488 $23.9 Million
Q3 2023 Nov 15, 2023	SELL	$27.57 - $32.91 $258,165 - $308,169	-9,364 Reduced 1.01%	916,747 $25.3 Million
Q2 2023 Aug 11, 2023	BUY	$29.91 - $38.73 $124,096 - $160,690	4,149 Added 0.45%	926,111 $27.8 Million
Q1 2023 May 15, 2023	SELL	$34.93 - $42.03 $415,247 - $499,652	-11,888 Reduced 1.27%	921,962 $33.4 Million

Q4 2022 Feb 15, 2023	SELL	$31.09 - $37.88 $4.99 Million - $6.08 Million	-160,593 Reduced 14.67%	933,850 $33.3 Million
Q3 2022 Nov 15, 2022	SELL	$28.79 - $35.41 $1.01 Million - $1.24 Million	-34,984 Reduced 3.1%	1,094,443 $37 Million
Q2 2022 Aug 15, 2022	BUY	$25.33 - $34.25 $127,207 - $172,003	5,022 Added 0.45%	1,129,427 $32.7 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $1.96 Million - $2.27 Million	68,875 Added 6.53%	1,124,405 $36.3 Million
Q4 2021 Feb 15, 2022	BUY	$26.37 - $34.22 $1.02 Million - $1.33 Million	38,865 Added 3.82%	1,055,530 $30.8 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $369,413 - $492,603	15,693 Added 1.57%	1,016,665 $27.1 Million
Q2 2021 Aug 26, 2021	SELL	$26.72 - $33.19 $6.15 Million - $7.64 Million	-230,256 Reduced 18.7%	1,000,972 $30.8 Million
Q1 2021 May 14, 2021	BUY	$24.15 - $31.45 $228,869 - $298,051	9,477 Added 0.78%	1,231,228 $32.2 Million
Q4 2020 Feb 16, 2021	BUY	$17.7 - $25.81 $7.16 Million - $10.4 Million	404,247 Added 49.45%	1,221,751 $30.7 Million
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $2.64 Million - $3.28 Million	130,799 Added 19.05%	817,504 $17 Million
Q2 2020 Aug 17, 2020	BUY	$17.09 - $24.89 $1.89 Million - $2.76 Million	110,701 Added 19.22%	686,705 $16.3 Million
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $1.7 Million - $2.9 Million	-117,318 Reduced 16.92%	576,004 $10.4 Million
Q4 2019 Feb 14, 2020	SELL	$19.93 - $29.13 $2.21 Million - $3.24 Million	-111,087 Reduced 13.81%	693,322 $16.4 Million
Q3 2019 Nov 15, 2019	SELL	$25.47 - $33.37 $740,896 - $970,699	-29,089 Reduced 3.49%	804,409 $22.1 Million
Q2 2019 Aug 15, 2019	SELL	$29.96 - $38.87 $101,864 - $132,158	-3,400 Reduced 0.41%	833,498 $27.6 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $2.84 Million - $3.64 Million	86,622 Added 11.55%	836,898 $29.3 Million
Q4 2018 Feb 15, 2019	BUY	$30.84 - $49.51 $1.57 Million - $2.52 Million	50,844 Added 7.27%	750,276 $24.9 Million
Q3 2018 Nov 15, 2018	BUY	$42.7 - $56.55 $32,281 - $42,751	756 Added 0.11%	699,432 $35.2 Million
Q2 2018 Aug 15, 2018	SELL	$44.1 - $59.85 $8.03 Million - $10.9 Million	-182,098 Reduced 20.67%	698,676 $41.8 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $4.65 Million - $5.87 Million	125,162 Added 16.56%	880,774 $40.3 Million
Q4 2017 Feb 15, 2018	BUY	$36.4 - $42.6 $47,611 - $55,720	1,308 Added 0.17%	755,612 $30.1 Million
Q3 2017 Nov 15, 2017	SELL	$36.75 - $49.65 $67,473 - $91,157	-1,836 Reduced 0.24%	754,304 $30.2 Million
Q2 2017 Aug 21, 2017	BUY	N/A	756,140	756,140 $32.6 Million

Others Institutions Holding SUPN

# of Institutions

260

Shares Held

57.3M

Call Options Held

84.1K

Put Options Held

61.2K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.45B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ashford Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ashford Capital Management Inc with notifications on news.

Account

Ashford Capital Management Inc Supernus Pharmaceuticals, Inc. Transaction History